Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred Yung

Showing results (201-210 of 217) with videos related to

Pageof 22
Sort By:
Neuro-Oncology|September 21, 2014
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastomaMarta Penas-Prado, Kenneth R Hess, Michael J Fisch, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2017
PAF promotes stemness and radioresistance of glioma stem cellsDerrick Sek Tong Ong, Baoli Hu, Yan Wing Ho, et al.
Nature Communications|April 27, 2025
Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trialShiao-Pei Weathers, Xiqi Li, Haifeng Zhu, et al.
Biorxiv : the Preprint Server for Biology|June 6, 2025
Oncogenic drivers shape the tumor microenvironment in human gliomasBo Zhao, Chae Yun Cho, Lingqun Ye, et al.
Neuro-Oncology|November 23, 2019
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophagesJohn de Groot, Marta Penas-Prado, Kristin Alfaro-Munoz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Cancer Discovery|May 17, 2012
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitorsIgor Vivanco, H Ian Robins, Daniel Rohle, et al.
Cell|January 30, 2016
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse GliomaMichele Ceccarelli, Floris P Barthel, Tathiane M Malta, et al.
Nature Genetics|December 5, 2022
The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and locationIlon Liu, Li Jiang, Erik R Samuelsson, et al.
Nature Genetics|May 9, 2025
Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomicsAvishay Spitzer, Kevin C Johnson, Masashi Nomura, et al.
Pageof 22

Showing results (201-210 of 217) with videos related to

Sort By:
Pageof 22
Neuro-Oncology|September 21, 2014
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastomaMarta Penas-Prado, Kenneth R Hess, Michael J Fisch, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2017
PAF promotes stemness and radioresistance of glioma stem cellsDerrick Sek Tong Ong, Baoli Hu, Yan Wing Ho, et al.
Nature Communications|April 27, 2025
Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trialShiao-Pei Weathers, Xiqi Li, Haifeng Zhu, et al.
Biorxiv : the Preprint Server for Biology|June 6, 2025
Oncogenic drivers shape the tumor microenvironment in human gliomasBo Zhao, Chae Yun Cho, Lingqun Ye, et al.
Neuro-Oncology|November 23, 2019
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophagesJohn de Groot, Marta Penas-Prado, Kristin Alfaro-Munoz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Cancer Discovery|May 17, 2012
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitorsIgor Vivanco, H Ian Robins, Daniel Rohle, et al.
Cell|January 30, 2016
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse GliomaMichele Ceccarelli, Floris P Barthel, Tathiane M Malta, et al.
Nature Genetics|December 5, 2022
The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and locationIlon Liu, Li Jiang, Erik R Samuelsson, et al.
Nature Genetics|May 9, 2025
Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomicsAvishay Spitzer, Kevin C Johnson, Masashi Nomura, et al.
Pageof 22